๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Treatment of chronic hepatitis C with interferon alfa-n3: A multicenter, randomized, open-label trial

โœ Scribed by DM Simon; SC Gordon; MM Kaplan; RS Koff; F Regenstein; G Everson; YM Lee; F Weiner; A Silverman; T Plasse; D Fedorczyk; M Liao

Book ID
118686586
Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
219 KB
Volume
25
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Treatment of chronic hepatitis C with in
Treatment of chronic hepatitis C with interferon alfa-n3: A multicenter, randomized, open-label trial
โœ D M Simon; S C Gordon; M M Kaplan; R S Koff; F Regenstein; G Everson; Y M Lee; F ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 217 KB ๐Ÿ‘ 2 views

We studied the antiviral effectiveness and safety of interferon alfa-n3, a natural alpha interferon which contains multiple interferon species, in the treatment of previously untreated patients with chronic hepatitis C. Seventy-seven patients were randomized to receive either 1.0, 2.5, 5.0, or 10.0

Treatment of chronic hepatitis C with co
Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial
โœ M J Tong; K R Reddy; W M Lee; P J Pockros; J C Hoefs; E B Keeffe; F B Hollinger; ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 222 KB ๐Ÿ‘ 2 views

AND THE CONSENSUS INTERFERON STUDY GROUP 15 tion. Efficacy was assessed by normalization of serum alanine This multicenter, randomized, controlled, double-blind, transaminase (ALT) concentration and decrease in serum hepphase III study in 704 patients with chronic hepatitis C infecatitis C virus (HC

Response to higher doses of interferon a
Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial
โœ K L Lindsay; G L Davis; E R Schiff; H C Bodenheimer; L A Balart; J L Dienstag; R ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 193 KB ๐Ÿ‘ 2 views

JANICE ALBRECHT, 12 AND THE HEPATITIS INTERVENTIONAL THERAPY GROUP\* with continued therapy at that dose; however, a propor-To evaluate response rates to 3, 5, or 10 million units tion of patients who do not respond to 12 weeks of treat-(MU) of interferon alfa-2b, given thrice weekly, and to ment wi